[1] Ning Z, Xian YH, Yi ND, et al.The role of miRNAs in colorectal cancer progression and chemoradiotherapy[J]. Biomedicine & Pharmacotherapy, 2021, 134: 111099. [2] Lewandowska AM, Hartman ML, Czyz M, et al.Inhibitors of HSP90 in melanoma[J]. Apoptosis, 2020, 25(M111): 12-28. [3] Wei H, Hui XH.BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review)[J]. Oncology reports, 2018, 40(1): 3-15. [4] Kale S, Korcum AF, Dündar E, et al.HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators[J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(2): 253-262. [5] Rehan A, Jaikee KS, Amoolya W, et al.Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)[J]. International Journal of Molecular Medicine, 2021, 47(3): 1. [6] Akhil K, Sourabh S, Sreedhar AS, et al.Hsp90 chaperone facilitates E2F12-dependent gene transcription in human breast cancer cells[J]. European Journal of Cell Biology, 2021, 100(1): 151148-151157. [7] Cindy G, Alexandre P, Christophe L, et al.Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2[J]. Biochim Biophys Acta, 2013, 1833(6): 1356-1366. [8] Md AA, Md SS, Tahmina A, et al.Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer[J]. Life Sciences, 2021, 268: 118999. [9] Liu Y, Liao SJ, Bennett S, et al.STAT3 and its targeting inhibitors in osteosarcoma[J]. Cell Prolif, 2021, 54(2): e12974-e12974. [10] Su T, Wang YP, Wang XN, et al.The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin A[J]. Life Sciences, 2020, 241: 117169 . |